rare-disease-sales-compensation 
The Marketing Advantage
MAY 8, 2023
May 9, 2023 Since the Orphan Drug Act was passed in 1983, the number of products being researched and approved for rare and orphan diseases has increased dramatically, offering hope and life-saving treatments for the millions of patients affected by these often under-served conditions.
The Marketing Advantage
FEBRUARY 26, 2024
February 26, 2024 The rare disease and orphan drug space remains one of the most difficult markets in which to set accurate and equitable territory-level goals. Territory-Level Goal Setting for Rare Disease Products Too often, common methodologies used to set goals for rare disease products are ineffective.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
MAY 26, 2021
Humira, a drug used to treat rheumatoid arthritis and other autoimmune diseases, is the highest grossing drug in the world. Hundreds of Millions in Executive Compensation and Bonuses: Since separating from Abbott in 2013, AbbVie has paid its highest-ranking executives over $480 million in compensation. net revenue for Humira.
pharmaphorum
DECEMBER 23, 2022
Rarely are organisations able to view HCP relationships holistically – across clinical, medical, and sales – or reap the benefits of creating a unified understanding of the customer. Incentive compensation models will reward the right omnichannel behaviours. A unified view of the HCP will emerge from clinical to commercial.
The Marketing Advantage
NOVEMBER 30, 2021
The severity and impact of the Omicron variant is still being assessed, forcing biopharma companies to grapple with immense uncertainty during one of the most important planning periods of the year, including 2022 sales incentive compensation planning. TERRITORY-LEVEL CONTINGENCY PLAN. 100%/80%) in order to make the territory whole.
European Pharmaceutical Review
AUGUST 26, 2022
Moderna claims that, when COVID-19 emerged, neither company had the same level of experience with “developing mRNA vaccines for infectious diseases” as Moderna, adding: “they knowingly followed Moderna’s lead in developing their own vaccine.”. ” But why sue now?
PharmaKinnex
SEPTEMBER 2, 2022
The pharmaceutical industry needs to be shifting its sales and marketing tactics to fit into this new, blended environment…this includes developing a new sales compensation model for the future…] ². According to recent estimates, as many as 30% of pharmaceutical sales were conducted virtually in 2020².
Expert insights. Personalized for you.
52 
Let's personalize your content